Literature DB >> 21748549

Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey.

Katsutoshi Tokushige1, Etsuko Hashimoto, Yoshinori Horie, Makiko Taniai, Susumu Higuchi.   

Abstract

PURPOSE: To clarify the etiology of hepatocellular carcinoma (HCC) in Japanese patients with non-viral liver disease, we performed a nationwide survey. The influence of obesity, lifestyle-related diseases, and alcohol consumption was focused on.
METHODS: A nationwide survey of 14,530 HCC patients was conducted in 2009. Clinical features were studied for HCC patients with nonalcoholic fatty liver disease (NAFLD-HCC; n = 292), alcoholic liver disease (ALC-HCC; n = 991), and chronic liver disease of unknown etiology (unknown HCC; n = 614). The unknown HCC was divided into two subgroups, a no alcohol intake group and a modest alcohol intake group.
RESULTS: ALC-HCC accounted for 7.2% of all HCC, followed by unknown HCC (5.1%) and NAFLD-HCC (2.0%). The characteristics of these three groups were clearly different (median age was 72 years for NAFLD-HCC, 68 years for ALC-HCC, and 73 years for unknown HCC, p < 0.01; female gender was 38, 4, and 37%, respectively, p < 0.01). Obesity and lifestyle-related diseases were significantly more frequent in NAFLD-HCC than in ALC-HCC and unknown HCC. The no alcohol intake subgroup of unknown HCC showed female predominance (58%) and was older, without a high prevalence of obesity and lifestyle-related diseases. In contrast, the modest alcohol intake subgroup showed the same trends regarding gender, body mass index, prevalence of lifestyle-related diseases, and liver function as the ALC-HCC group.
CONCLUSIONS: The clinical features of ALC-HCC, NAFLD-HCC, and unknown HCC were clearly different. Modest intake of alcohol might have a more significant role in hepatic carcinogenesis than is presently thought.

Entities:  

Mesh:

Year:  2011        PMID: 21748549     DOI: 10.1007/s00535-011-0431-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  31 in total

1.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

Review 2.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 3.  Hepatocellular carcinoma: epidemiology, risk factors, and screening.

Authors:  Morris Sherman
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

4.  Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH.

Authors:  Yoko Yoshioka; Etsuko Hashimoto; Satoru Yatsuji; Hiroyuki Kaneda; Makiko Taniai; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2004-12       Impact factor: 7.527

Review 5.  Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.

Authors:  Abby B Siegel; Andrew X Zhu
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

6.  Etiology of liver cirrhosis in Japan: a nationwide survey.

Authors:  Kojiro Michitaka; Shuhei Nishiguchi; Yutaka Aoyagi; Yoichi Hiasa; Yoshio Tokumoto; Morikazu Onji
Journal:  J Gastroenterol       Date:  2009-09-30       Impact factor: 7.527

7.  Obesity and cancer risk: a Danish record-linkage study.

Authors:  H Møller; A Mellemgaard; K Lindvig; J H Olsen
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

8.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

9.  Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences.

Authors:  Hayato Nakagawa; Shin Maeda; Haruhiko Yoshida; Ryosuke Tateishi; Ryota Masuzaki; Takamasa Ohki; Yoku Hayakawa; Hiroto Kinoshita; Minoru Yamakado; Naoya Kato; Shuichiro Shiina; Masao Omata
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

10.  Correlation of clinical characteristics with detection of hepatitis B virus X gene in liver tissue in HBsAg-negative, and HCV-negative hepatocellular carcinoma patients.

Authors:  Yoichiro Higashi; Shuji Tada; Shuichi Miyase; Kazuhiko Hirota; Haruo Imamura; Takihiro Kamio; Hironobu Suko
Journal:  Liver       Date:  2002-10
View more
  35 in total

1.  Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.

Authors:  Christopher Leung; Sern Wei Yeoh; Desmond Patrick; Shara Ket; Kaye Marion; Paul Gow; Peter W Angus
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 2.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

3.  Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.

Authors:  Nicole M Kettner; Horatio Voicu; Milton J Finegold; Cristian Coarfa; Arun Sreekumar; Nagireddy Putluri; Chinenye A Katchy; Choogon Lee; David D Moore; Loning Fu
Journal:  Cancer Cell       Date:  2016-11-23       Impact factor: 31.743

Review 4.  Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?

Authors:  Nicolas Goossens; Yujin Hoshida
Journal:  Gastroenterology       Date:  2016-01-16       Impact factor: 22.682

5.  Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: A community-based cohort study.

Authors:  Naoko Tsubouchi; Hirofumi Uto; Kotaro Kumagai; Fumisato Sasaki; Shuji Kanmura; Masatsugu Numata; Akihiro Moriuchi; Makoto Oketani; Akio Ido; Katsuhiro Hayashi; Kazunori Kusumoto; Kazuya Shimoda; Sherri O Stuver; Hirohito Tsubouchi
Journal:  Hepatol Res       Date:  2013-02-18       Impact factor: 4.288

Review 6.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

7.  Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus.

Authors:  Toshihide Shima; Hirofumi Uto; Kohjiro Ueki; Toshinari Takamura; Yutaka Kohgo; Sumio Kawata; Kohichiroh Yasui; Hyohun Park; Naoto Nakamura; Tatsuaki Nakatou; Nobuyoshi Tanaka; Atsushi Umemura; Masayuki Mizuno; Junko Tanaka; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2012-08-22       Impact factor: 7.527

8.  Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.

Authors:  Xianbin Cai; Chongye Fang; Shuhei Hayashi; Shumei Hao; Mingming Zhao; Hiroko Tsutsui; Shuhei Nishiguchi; Jun Sheng
Journal:  J Gastroenterol       Date:  2016-01-21       Impact factor: 7.527

9.  Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey.

Authors:  Katsutoshi Tokushige; Hideyuki Hyogo; Tomoaki Nakajima; Masafumi Ono; Takumi Kawaguchi; Koichi Honda; Yuichiro Eguchi; Yuichi Nozaki; Miwa Kawanaka; Saiyu Tanaka; Kento Imajo; Yoshio Sumida; Yoshihiro Kamada; Hideki Fujii; Yasuaki Suzuki; Tomomi Kogiso; Yoshiyasu Karino; Kensuke Munekage; Ryoko Kuromatsu; Satoshi Oeda; Mikio Yanase; Kohjiro Mori; Yuji Ogawa; Yuya Seko; Tetsuo Takehara; Yoshito Itoh; Atsushi Nakajima; Kazuyuki Kanemasa; Ken Nishino; Naohiko Masaki; Hirokazu Takahashi; Masataka Seike; Takuji Torimura; Toshiji Saibara; Joji Toyota; Kazuaki Chayama; Etsuko Hashimoto
Journal:  J Gastroenterol       Date:  2015-10-11       Impact factor: 7.527

Review 10.  NAFLD, NASH and liver cancer.

Authors:  Gregory A Michelotti; Mariana V Machado; Anna Mae Diehl
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-01       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.